Trial Profile
A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD) Plus COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PEGHOPE
- Sponsors Roche
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jan 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.